UOC
VRDN icon

UBS O'Connor’s Viridian Therapeutics VRDN Stock Holding History

UBS O'Connor’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-131,294
Closed -$1.84M – 452
2025
Q2 		$1.84M Buy
131,294
+24,206
+23% +$329K 0.05% 170
2025
Q1 		$1.44M Buy
107,088
+62,488
+140% +$1.06M 0.03% 151
2024
Q4 		$855K Buy
+44,600
New +$970K 0.02% 243
2024
Q3 		– Sell
-10,057
Closed -$131K – 613
2024
Q2 		$131K Sell
10,057
-6,400
-39% -$88.6K ﹤0.01% 423
2024
Q1 		$288K Sell
16,457
-13,543
-45% -$263K 0.01% 371
2023
Q4 		$653K Sell
30,000
-54,836
-65% -$866K 0.02% 322
2023
Q3 		$1.3M Buy
84,836
+10,000
+13% +$191K 0.02% 299
2023
Q2 		$1.78M Buy
74,836
+11,293
+18% +$290K 0.04% 320
2023
Q1 		$1.62M Sell
63,543
-2,917
-4% -$93.5K 0.04% 358
2022
Q4 		$1.94M Sell
66,460
-15,410
-19% -$355K 0.04% 469
2022
Q3 		$1.68M Buy
81,870
+47,481
+138% +$854K 0.02% 671
2022
Q2 		$398K Buy
34,389
+14,389
+72% +$193K ﹤0.01% 826
2022
Q1 		$370K Buy
+20,000
New +$384K ﹤0.01% 758

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

UBS O'Connor's VRDN Position: Q3 2025 in Review

UBS O'Connor sold out of Viridian Therapeutics (VRDN) in Q3 2025, closing a stake of 131,294 shares — an estimated $1.84M sold.

UBS O'Connor first reported a position in VRDN in Q1 2022 and held it in 13 quarters. The position peaked at $1.94M in Q4 2022. 169 funds tracked by Wall St. Rank hold VRDN as of Q3 2025.

  • UBS O'Connor reported no remaining Viridian Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 131,294 Viridian Therapeutics shares in Q3 2025, an estimated $1.84M.
  • UBS O'Connor first reported a position in Viridian Therapeutics in Q1 2022 and held it in 13 quarters.
  • UBS O'Connor's Viridian Therapeutics position peaked at $1.94M in Q4 2022.
  • 169 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.